The European Commission says it is in “close touch” with member states and pharmaceutical companies about the impact of the US Most Favored Nation policy and is supporting voluntary collaboration to counter any threats it poses.
The European Commission says it is in “close touch” with member states and pharmaceutical companies about the impact of the US Most Favored Nation policy and is supporting voluntary collaboration to counter any threats it poses.